Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
LILRA3 Biologics Sequence Review Report 2026: Leukocyte immunoglobulin-like receptor subfamily A member 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LILRA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LILRA2 Biologics Sequence Review Report 2026: Leukocyte immunoglobulin-like receptor subfamily A member 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LILRA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LILRA1 Biologics Sequence Review Report 2026: Leukocyte immunoglobulin-like receptor subfamily A member 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LILRA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ILDR1 Biologics Sequence Review Report 2026: Immunoglobulin-like domain-containing receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ILDR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL9R Biologics Sequence Review Report 2026: Interleukin-9 receptor Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL9R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL36RN Biologics Sequence Review Report 2026: Interleukin-36 receptor antagonist protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL36RN protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL22RA2 Biologics Sequence Review Report 2026: Interleukin-22 receptor subunit alpha-2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL22RA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL20RB Biologics Sequence Review Report 2026: Interleukin-20 receptor subunit beta Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL20RB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL20RA Biologics Sequence Review Report 2026: Interleukin-20 receptor subunit alpha Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL20RA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL1RL2 Biologics Sequence Review Report 2026: Interleukin-1 receptor-like 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL1RL1 Biologics Sequence Review Report 2026: Interleukin-1 receptor-like 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL1RAP Biologics Sequence Review Report 2026: Interleukin-1 receptor accessory protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.